sb 203580 has been researched along with Multiple Myeloma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Frost, P; Fukunaga, R; Gera, J; Hoang, B; Lichtenstein, A; Shi, Y; Yang, Y | 1 |
| Ballon, DJ; Chang, CC; Cheng, HY; Feng, Y; Huang, J; Liu, S; Mo, A; Rice, L; Wen, J; Zu, Y | 1 |
2 other study(ies) available for sb 203580 and Multiple Myeloma
| Article | Year |
|---|---|
MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells.
Topics: 5' Untranslated Regions; Aniline Compounds; Animals; Butadienes; Cell Line, Tumor; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Genes, myc; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Mice; Multiple Myeloma; Nitriles; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Biosynthesis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-myc; Purines; Pyridines; RNA Interference; RNA, Messenger; RNA, Small Interfering; Sirolimus; TOR Serine-Threonine Kinases; Up-Regulation | 2013 |
P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Imidazoles; Molecular Chaperones; Multiple Myeloma; Neoplasm Proteins; Oxides; p38 Mitogen-Activated Protein Kinases; Pyridines; Signal Transduction; Tumor Cells, Cultured; Up-Regulation | 2008 |